Over time, transthyretin amyloidosis (ATTR) can damage the nerves, heart, and other organs. This may lead to complications like heart problems, nerve damage, and trouble with everyday bodily functions ...

The life expectancy for transthyretin (ATTR) amyloidosis varies from person to person. Your age, overall health, and primary symptoms all play a role. Transthyretin amyloidosis (ATTR) is a rare ...

Purpose: Retinal angiopathy represents a well-known ocular manifestation of hereditary transthyretin amyloidosis (ATTRv). Until recently, there have been no reports on retinal changes in ATTRwt. In ...

Transthyretin cardiac amyloidosis (ATTR-CA) is a frequent cause of heart failure (HF) in older Black individuals, particularly in the oldest men, the prospective SCAN-MP study affirms. The highest ...

A tiny implant that beams images straight to the retina, bypassing a damaged cornea altogether, could give sight back to millions living with corneal blindness – no donor tissue required. Human trials ...

Using only a small voltage of direct current, a custom reshaping lens, and gentle pressure, a noninvasive surgical technique has been developed for correcting corneal refractive errors. To date, this ...

A quiet revolution in care is helping patients with cardiac amyloidosis, a form of heart failure that long stumped doctors. By Simar Bajaj When James Hicks, 75, was diagnosed with heart failure, it ...

Artificial intelligence can detect cardiac amyloidosis from a short video of a heartbeat, according to new research in the European Heart Journal. Cardiac amyloidosis results when misshaped or ...

A drug that AstraZeneca singled out as one of its key potential revenue growth drivers in the next decade has failed a pivotal study in light chain amyloidosis, a rare disease with few treatment ...

Anselamimab did not meet main goal in overall study population Therapy shows improvement in pre-specified patient subgroup AstraZeneca plans to share data with regulators July 16 (Reuters) - ...

The antibody anselamimab, which AstraZeneca picked up in its 2021 purchase of Caelum Biosciences, failed to improve survival and reduce hospitalizations, but the company sees promise in data from an ...

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from the brains of people destined to develop Alzheimer’s dementia can delay the ...